Sweden a leader in advanced therapies 2030
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB - RISE Medicinteknik, Göteborg |
| Funding from Vinnova | SEK 25 000 000 |
| Project duration | November 2019 - November 2024 |
| Status | Ongoing |
| Venture | Vision-driven health |
| Call | Establishment of vision-driven innovation milieus |
Purpose and goal
The project aims, based on a common vision that brings together relevant actors, to achieve a long-term transformation of the innovation system for advanced therapies based on gene and cell therapeutic products (so-called ATMP). Important intermediate goals are a national coordination and increased internationalization, better conditions for the development and accessibility of advanced therapies, as well as increased knowledge of the area to secure future competence needs.
Expected effects and result
The project should within a five-year period have contributed to increased national collaboration between public and private actors leading to better conditions in Sweden for both development and implementation in healthcare of ATMP and a stronger international position for Sweden within the field. Expected effects are that Swedish healthcare and patients benefit from developments in the area and that Sweden becomes attractive to foreign actors and investments within area.
Planned approach and implementation
The project is based on cross-sectoral collaboration between healthcare, business, government and other actors, who jointly carry out activities and initiatives towards the goals and vision. A core team of seven people with different competences and perspectives will drive, coordinate and continuously monitor results and effects. The project execution will be based on an inclusive attitude and collaboration that creates synergies with other initiatives and structures in the area.